In January 2015, the South African National Department of Health released new consolidated guidelines for the prevention of mother to child transmission (PMTCT) of HIV, in line with the World Health Organization's (WHO) PMTCT Option B+. Implementing these guidelines should make it possible to eliminate mother to child transmission (MTCT) of HIV and improve long-term maternal and infant outcomes. The present article summarises the key recommendations of the 2015 guidelines and highlights current gaps that hinder optimal implementation; these include late antenatal booking (as a result of poor staff attitudes towards 'early bookers' and foreigners, unsuitable clinic hours, lack of transport to facilities, quota systems being applied to antenatal clients and clinic staff shortages); poor compliance with rapid HIV testing protocols; weak referral systems with inadequate follow-up; inadequate numbers of laboratory staff to handle HIV-related monitoring procedures and return of results to the correct facility; and inadequate supply chain management, leading to interrupted supplies of antiretroviral drugs. Additionally, recommendations are proposed on how to address these gaps. There is a need to evaluate the implementation of the 2015 guidelines and proactively communicate with ground-level implementers to identify operational bottlenecks, test solutions to these bottlenecks, and develop realistic implementation plans. 
Introduction

Context and summary of 2015 prevention of mother to child transmission guidelines
South Africa has the highest HIV incidence rates globally, and is the largest provider of antiretroviral therapy in the world. 1, 2 In January 2015, the South African National Department of Health (NDoH) released new national consolidated guidelines, including an approach akin to World Health Organization (WHO) Option B+ for the prevention of mother to child transmission (PMTCT) of HIV. 3 These guidelines harmonise triple antiretroviral treatment (ART) regimens for infants and young children, adolescents, pregnant and breastfeeding women, and adults to facilitate continuity of care. The guidelines stipulate lifelong ART for all pregnant and breastfeeding women and HIV-positive infants regardless of their CD4 cell count.
3 Box 1 summarises the main differences between the 2015 3 and 2013 4 PMTCT guidelines. Specific algorithms have been developed for women with comorbidities (e.g. active psychiatric illness, renal dysfunction and/ or anaemia) and these remain unchanged compared with the 2013 South African guidelines. 3, 4 The 2015 guidelines highlight the need to improve access to testing and treatment in general, to achieve the 90/90/90 target (90% coverage for HIV testing, 90% coverage for ART uptake amongst HIV-positive patients, and viral suppression of 90% of patients on ART) and to prioritise HIV prevention and treatment amongst adolescents. 3 Despite the complexity of the new policy, its 'treatment as prevention' approach amongst pregnant and breastfeeding women could move South Africa closer to achieving the fourth and fifth millennium development goals and the post-2015 sustainable development goals.
Health systems' readiness to implement the new guidelines
System gaps that may hinder successful implementation of the 2015 South African prevention of mother to child transmission guidelines In our opinion, there are five main requirements for successful implementation of the 2015 PMTCT guidelines: (1) early presentation at the health facility to access care (i.e. early antenatal booking), (2) universal antenatal HIV testing based on high-quality standardised operating procedures, with repeat testing of HIV-negative women, (3) immediate referral into appropriate care and retention in care, (4) adequate coverage of appropriate laboratory systems and (5) uninterrupted drug supplies. These require appropriate actions within the health system and amongst sufficiently informed and empowered individual motherinfant pairs. Box 2 presents a summary of the main health system and community gaps in optimal implementation of the 2015 PMTCT guidelines; these are explained in more detail below.
Late antenatal booking
Since 2001, South Africa has improved access to antenatal care, HIV testing and ART provision for pregnant women. Currently, antenatal care uptake is over 95%; HIV testing is offered by over 95% of health facilities, and more than 87% of HIV-positive pregnant women receive some form of ART. 3, 5 However, the District Health Information System shows that in 2011/2012 only 40.2% (range 33.6% in Eastern Cape to 56.2% in Western Cape) of pregnant women had their first antenatal booking visit before 20 weeks' gestation, highlighting the first key bottleneck to successful guideline implementation. 6 A study in North-West Province identified a variety of reasons for late booking, including late pregnancy disclosure amongst teenagers, fear of HIV testing, non-caring nurse attitudes, cultural beliefs that dissuade early revealing of pregnancy, lack of transport and unsuitable clinic opening hours. 6 These findings were corroborated by research in Johannesburg which showed that 54% of pregnant women sought antenatal care later than 5 months' gestation. 7 Solarin and Black found that almost half of new mothers interviewed reported that their first antenatal booking was not accepted by health facilities for various reasons including (1) they needed 'to make a booking appointment', (2) they did not have a South African identity document and (3) clinics had reached their quota for the day. 7 These obstacles delay first antenatal booking and thus HIV screening, ART initiation and detection of treatment failure amongst pregnant women on ART as recommended by the 2015 South African PMTCT guidelines.
Key changes between the 2013 and January 2015 South Africa prevention of mother to child transmission guidelines.
South African PMTCT guideline New January 2015 South African PMTCT guideline
No mention of HIV testing amongst children.
Children aged ≥ 12 years may self-consent to an HIV test if they are of sufficient maturity to understand the benefits, risk and social implications.
Re-testing of HIV-negative mothers or mothers of unknown HIV status: should be tested for HIV at 6 weeks, 3 months, 9 months and 1 year postpartum, particularly if they are breast feeding.
Re-testing of HIV-negative mothers:
• 3-monthly through pregnancy • at labour/delivery • at 6-week infant immunisation visit (to identify newly exposed babies who need HIV testing) • 12-weekly throughout breastfeeding till 24 months if breastfeeding continued. Efavirenz (EFV) not used in first trimester of pregnancy amongst women on ART.
Efavirenz (EFV) used in first trimester of pregnancy amongst women on ART.
Viral load monitoring at first ANC if ART initiated before pregnancy and at 6 and 12 months post initiation.
Viral load monitoring at first ANC if ART initiated before pregnancy or within 3 months if ART initiated antenatally or during breastfeeding. Thereafter 6-monthly viral load monitoring.
Daily infant nevirapine for 6 weeks from as soon as possible post delivery.
As for 2013 plus infant nevirapine could continue for 12 weeks if maternal ART adherence has been suboptimal or maternal viral load > 1000 copies/mL or mother is newly diagnosed during breastfeeding. For newly diagnosed HIV-positive breastfeeding mothers, infant AZT and nevirapine should be initiated immediately. If infant PCR is negative, infant AZT can stop; but infant nevirapine should continue for 12 weeks. In HIV exposed infants < 18 months, infant nevirapine prophylaxis can be initiated if infant HIV rapid test result is not available or is positive, whilst awaiting infant's PCR result.
Infant PCR testing to be conducted at:
• birth in symptomatic infants failing to thrive (includes low birth weight, haematological abnormality such as anaemia or thrombocytopaenia, congenital pneumonia, hepatosplenomegaly, extensive oral candidiasis, significant lymphadenopathy, any opportunistic infections) • 6 weeks in all HIV-exposed infants • 6 weeks post cessation of breastfeeding if aged < 18 months and rapid HIV test if aged ≥ 18 months • rapid HIV testing at 18 months. Abandoned infants should receive NVP < 72 hours post delivery and continued until HIV-exposure status has been determined. If the HIV rapid/ELISA test is positive, continue nevirapine until 6 weeks of age and do a PCR at 6 weeks. If the HIV rapid test result cannot be determined within 2 hours of encountering an abandoned baby, a stat dose of NVP is warranted.
• birth, or as soon as possible after birth amongst all HIV exposed infants • 6 weeks in all HIV-exposed infants not testing positive at birth • 10 weeks in infants not testing HIV positive at birth • 16 weeks in infants receiving 12 weeks nevirapine • 6 weeks post cessation of breastfeeding if aged < 18 months and rapid HIV tests if aged ≥ 18 months • rapid HIV testing at 18 months for all HIV-exposed infants, for infants born to mothers of unknown HIV status, and for infants breastfed by a woman of unknown HIV status. For infants < 18 months, HIV rapid testing can be conducted to determine infant HIVexposure. Abandoned infants -protocol as for 2013 guidelines. 
Late referral into care and poor retention in care
Appropriate, timely referrals and linkages to care are needed antenatally and post delivery to facilitate uptake of and retention in care. Over 90% of facilities assessed during a national South African Medical Research Council (SAMRC) review conducted in 2010 had a referral system for infant and adult ART clients. 5 Similarly, an Eastern Cape study found that 100% of facilities reported appropriate referral mechanisms for HIV-positive women. 8 However, in the MRC review, 38% of facilities did not make appointments for their patients at referral centres, and only 50% of clinics followed up whether clients engaged with care at the referral site. 5 From our research and clinical experience, postnatal loss to follow-up is particularly high in South Africa. Poor information systems and documentation contribute to difficulties with tracing such patients. In Malawi, loss to follow-up was five times higher for women who started ART during pregnancy and two times higher for women who started ART whilst breastfeeding than for women who started ART with WHO stage 3/4 disease or CD4 cell count ≤ 350 cells/µL. 9 These data highlight the risk of poor retention in care postnatally and emphasise the need for robust referral systems, integrated services and effective tracking mechanisms to retain, or re-engage, women in ART care post delivery.
Limited laboratory capacity
Laboratory capacity is needed for (1) viral load monitoring to identify poor adherence and treatment failure -a vitally important step in PMTCT programme success, (2) CD4 cell count to identify women who need cryptococcal antigen screening or cotrimoxazole prophylaxis, (3) routine antenatal bloods for ART toxicity monitoring and (4) repeated polymerase chain reaction (PCR) testing of HIV-exposed infants from birth (for symptomatic infants) to 18 months; 3 laboratory capacity is accordingly a critical component of the PMTCT programme, and is key to timely referral into appropriate care. Previous challenges to implementing laboratory-based HIV tests in South Africa included difficulties processing large numbers of HIV-related specimens, high staff turn-over, and insufficient training in PCR techniques and CD4 measurements. 10 Consequently, experienced staff carry the burden of training new staff 10 and processing high quantities of specimens.
Interrupted drug supplies
By mid-2014, an estimated 2.6 million people were on ART in South Africa. 3 This number will further increase following the 2015 guideline implementation, creating additional demand for ART stock. Sustaining such ART programme expansion will necessitate more efficient, effective supply chain management and increased human resources. Yet the healthcare system remains plagued by frequent HIV medicines stock-outs and clinic staff shortages. Inadequate supply chain management and 'corruption' contribute to avoidable stock-outrelated treatment interruptions, 11 resulting in regimen modification at best or, at worst, drug discontinuation. 12 Considering the complexity of the new guidelines in part reflects South Africa's mature HIV epidemic, including increasing rates of highly experienced ART patients with treatment failure and drug resistance. The effects of recurrent stock-outs on adherence, viral loads and drug resistance should not be underestimated.
Recommendations
In light of the gaps identified above, we make several recommendations for optimal 2015 guideline implementation (Box 3).
BOX 2:
Summary of impediments to optimal prevention of mother to child transmission guideline implementation.
Late antenatal booking:
• poor staff attitudes towards 'early bookers' and foreigners • unsuitable clinic hours • lack of transport to facilities • quota systems applied to antenatal clients • clinic staff shortages and insufficient capacity.
Poor quality HIV testing:
• inadequate quality control • poor supervision • incomplete handling of discordant results
• poor data quality/documentation.
Linkage and retention in care:
• lack of service integration between (1) HIV-related care and routine maternal and child health services and (2) antenatal and postnatal services • poor information systems and documentation hinder tracking those lost to follow-up • weak referral systems.
Laboratory capacity:
• insufficient staff training • limited staff capacity to handle increased demand as monitoring and numbers increase • challenges with quickly communicating positive infant PCR results (e.g. facility
Internet access and working telephones).
Interrupted drug supplies:
• inadequate supply chain management • corruption.
Community level:
• late antenatal booking: > 50% book after 5 months' gestation • fear of HIV diagnosis • stigma associated with HIV infection and with teenage pregnancy • lack of demand for antiretroviral services owing to lack of awareness of benefits of treatment.
Conclusion
The January 2015 PMTCT guideline recommendations are of a very high standard and based on the best intentions to improve the management of both HIV-positive and HIVnegative women. By implementing these guidelines, it should be possible to eliminate MTCT, improve maternal and infant outcomes, and ensure that women remain virologically suppressed and engaged in lifelong ART care. However, the implementation challenges might have been underestimated. Evaluation of the implementation process is needed to identify key bottlenecks and develop realistic implementation plans. A proactive process of communicating with ground-level implementers is needed to understand their challenges and to address these through well recognised, quality improvement processes.
